Earnings Call · Q4 FY2023·2024-03-19

Q4 23EPS -1.20%·Rev n/aQ3 23EPS +19.78%·Rev n/aQ2 23EPS +6.67%·Rev n/aQ1 23EPS +2.25%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Tim McCarthy — Investor Relations or Communications

Sergio Traversa — Chief Executive Officer

Maged Shenouda — Chief Financial Officer

−2.7%1d on move date−3.3% vs SPY3d−15.6%5d−11.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access